Pacer Advisors Inc. Grows Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Pacer Advisors Inc. boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,742 shares of the company’s stock after buying an additional 1,729 shares during the period. Pacer Advisors Inc.’s holdings in IDEXX Laboratories were worth $6,943,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of IDXX. Ridgewood Investments LLC acquired a new position in shares of IDEXX Laboratories in the 2nd quarter worth approximately $27,000. Institutional & Family Asset Management LLC acquired a new position in IDEXX Laboratories during the second quarter worth $28,000. E Fund Management Hong Kong Co. Ltd. boosted its position in shares of IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after buying an additional 57 shares during the period. Mowery & Schoenfeld Wealth Management LLC grew its stake in shares of IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after buying an additional 60 shares in the last quarter. Finally, Strategic Investment Solutions Inc. IL purchased a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at $36,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 0.3 %

IDXX opened at $417.24 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39. The company has a market cap of $34.17 billion, a P/E ratio of 40.24, a PEG ratio of 3.65 and a beta of 1.36. The business’s 50-day simple moving average is $460.86 and its 200-day simple moving average is $480.68.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. During the same period in the prior year, the firm posted $2.53 earnings per share. The firm’s revenue was up 6.6% on a year-over-year basis. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 10.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of research analyst reports. Barclays lowered their target price on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Piper Sandler reissued a “neutral” rating and issued a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Finally, JPMorgan Chase & Co. cut their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $552.38.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.